Emily Hsu

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Clinical Sciences, Oncology +8

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Carol Moreno, Richard Greil, Fatih Demırkan et al. · The Lancet Oncology · 2018 · 548 citations

Medicine, Oncology, Pharmacology +13

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Petros Grivas, Ali Raza Khaki, Trisha M. Wise‐Draper et al. · Annals of Oncology · 2021 · 326 citations · Full text

Medicine, Infectious Diseases, Oncology +10

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 

Paul M. Barr, Carolyn Owen, Tadeusz Robak et al. · Blood Advances · 2022 · 269 citations · Full text

Medicine, Oncology, Pharmacology +14

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

Jennifer R. Brown, Peter Hillmen, Stephen J. O’Brien et al. · Leukemia · 2017 · 238 citations · Full text

Medicine, Hematology, Oncology +11